Neurogene Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.93	-	-	-
Cost of Revenue	4.51	0.9	47.51	42.26
Gross Profit	-3.58	-0.9	-47.51	-42.26
Selling, General & Admin	22.61	11.19	9.01	8.27
Research & Development	56.41	43.5	-	-
Operating Expenses	79.02	54.69	9.01	8.27
Operating Income	-82.61	-55.58	-56.52	-50.53
Interest Expense	-0.01	-0.01	-0	-
Interest & Investment Income	8.47	2.95	1.34	0.02
Other Non Operating Income (Expenses)	-0.99	-0.03	-0.01	-
EBT Excluding Unusual Items	-75.14	-52.67	-55.19	-50.52
Other Unusual Items	-	16.36	-	-
Pretax Income	-75.14	-36.32	-55.19	-50.52
Net Income	-75.14	-36.32	-55.19	-50.52
Preferred Dividends & Other Adjustments	-	-49.97	-	-
Net Income to Common	-75.14	13.65	-55.19	-50.52
Shares Outstanding (Basic)	18	0	0	4
Shares Outstanding (Diluted)	18	5	0	4
Shares Change (YoY)	277.22%	1080.37%	-90.26%	-
EPS (Basic)	-4.28	27.76	-139.88	-12.47
EPS (Diluted)	-4.28	2.93	-139.88	-12.47
Free Cash Flow	-71.41	-51.74	-55.05	-64.77
Free Cash Flow Per Share	-4.07	-11.11	-139.54	-15.99
Operating Margin	-8930.27%	-	-	-
Profit Margin	-8123.68%	-	-	-
Free Cash Flow Margin	-7720.11%	-	-	-
EBITDA	-79.36	-52.29	-53.32	-49.59
D&A For EBITDA	3.25	3.3	3.2	0.95
EBIT	-82.61	-55.58	-56.52	-50.53

Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q